<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01095770</url>
  </required_header>
  <id_info>
    <org_study_id>LAAPITUP</org_study_id>
    <nct_id>NCT01095770</nct_id>
  </id_info>
  <brief_title>Left Atrial Ablation With Permanent Pacemaker or ImplanTable Loop Recorder Follow-UP</brief_title>
  <acronym>LAAPITUP</acronym>
  <official_title>Left Atrial Ablation With Permanent Pacemaker or ImplanTable Loop Recorder Follow-UP</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eastbourne General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eastbourne General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is 3 fold:-

        1. To compare the efficacy and complication rates of 2 widely used methods, conventional
           irrigation tip ablation catheter (LASSO) and Ablation Frontiers ablation technology, of
           AF ablation for PAF.

        2. To evaluate the Reveal XT ILR as a long term accurate AF monitoring device as compared
           to the 'gold standard' DDD pacemaker Holter.

        3. To accurately evaluate, by continuous rhythm monitoring for 1 year, the efficacy of AF
           ablation therapy for PAF.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>April 2010</start_date>
  <completion_date type="Anticipated">November 2012</completion_date>
  <primary_completion_date type="Anticipated">April 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AF Burden</measure>
    <time_frame>12 Months</time_frame>
    <description>AF Burden post left atrial ablation is defined as the sum of the duration of all atrial tachyarrhythmias expressed as a percentage of the total observation period as assessed by PM Holters.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AF Burden</measure>
    <time_frame>12 months</time_frame>
    <description>Comparison of AF burden post PVI ablation using a conventional irrigation tip catheter with LASSO guidance (or equivalent) versus Ablation Frontiers Technology using the PVAC, MASC and TVAC catheters via standard trans-septal techniques.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AF Burden detected</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate the Reveal XT ILR as a long term accurate AF monitoring device as compared to the 'gold standard' DDD pacemaker Holter.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Arrhythmia frequency - symptomatic or asymptomatic.</measure>
    <time_frame>12 months</time_frame>
    <description>Arrhythmia Frequency is defined as the total number of atrial tachyarrhythmic episodes divided by the observation period, expressed as episodes per day as assessed by PM Holters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first episode of AF</measure>
    <time_frame>12 months</time_frame>
    <description>Time to persistent AF is defined as the time from ablation to the first recorded episode of AF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average AF duration</measure>
    <time_frame>12 months</time_frame>
    <description>Average arrhythmia duration is defined as the total duration of atrial arrhythmia divided by the total number of atrial arrhythmia episodes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to persistent AF.</measure>
    <time_frame>12 months</time_frame>
    <description>Time to persistent AF (atrial fibrillation episode lasting for 7 days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average SR duration.</measure>
    <time_frame>12 months</time_frame>
    <description>Average sinus rhythm duration is defined as the total duration of sinus rhythm from first atrial arrhythmic episode until last atrial arrhythmic episode divided by the number of atrial arrhythmic episodes minus 1.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Paroxysmal Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Ablation Frontiers Ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will undergo AF ablation using Ablation Frontiers Technology.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LASSO ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will undergo atrial fibrillation ablation with traditional LASSO technology</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reveal XT monitoring</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will be monitored pre and post ablation using a Reveal XT implantable loop recorder.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Permanent Pacemaker - dual chamber</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will be monitored pre and post ablation with a dual chamber permanent pacemaker</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>AF Ablation with Ablation Frontiers Technology</intervention_name>
    <description>AF Ablation with Ablation Frontiers Technology - PVAC, TVAC and MASC.</description>
    <arm_group_label>Ablation Frontiers Ablation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>AF Ablation with LASSO catheter</intervention_name>
    <description>AF Ablation with traditional LASSO catheter</description>
    <arm_group_label>LASSO ablation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Reveal XT</intervention_name>
    <description>Reveal XT implantable loop recorder monitored group</description>
    <arm_group_label>Reveal XT monitoring</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Permanent Dual Chamber Pacemaker</intervention_name>
    <description>This group will be monitored with a dual chamber pacemaker with advanced AF monitoring capabilities.</description>
    <arm_group_label>Permanent Pacemaker - dual chamber</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient aged 16-80 years old.

          -  Symptomatic PAF with AF episodes self terminating after at least 30 seconds but not
             longer than 24 hours. Preference is given to patients with AF episodes lasting no
             longer than 4 hours.

          -  PAF should have failed at least one drug therapy medical therapy.

          -  Patients must give written informed consent form prior to participating in this study.

        Exclusion Criteria:

          -  Patient is suffering with unstable angina in last 1 week.

          -  Patient has had a myocardial infarction within last 2 months.

          -  Patient is expecting or has had major cardiac surgery within last 2 months.

          -  Patient is participating in a conflicting study.

          -  Patient is mentally incapacitated and cannot consent or comply with follow-up.

          -  Patient has NYHA class III/ IV heart failure.

          -  Patients with severe valvular or ventricular dysfunction.

          -  Pregnancy.

          -  Patient suffers with other cardiac rhythm disorders.

          -  Recent coronary artery intervention or other factors suggesting clinical instability
             (ECG, clinical or laboratory findings)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen S Furniss, FRCP, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>East Sussex NHS Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>AN Sulke, FRCP, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>East Sussex NHS Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Steven J Podd, MBBS, MRCP, BA</last_name>
    <phone>01323 417400</phone>
    <phone_ext>4132</phone_ext>
    <email>steven.podd@esht.nhs.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Eastbourne District General Hospital</name>
      <address>
        <city>Eastbourne</city>
        <state>East Sussex</state>
        <zip>BN21 2UD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Steven J Podd, MBBS, MA, MRCP</last_name>
      <phone>01323 417400</phone>
      <phone_ext>4132</phone_ext>
      <email>steven.podd@esht.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Steven J Podd, MBBS, MA, MRCP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2010</study_first_submitted>
  <study_first_submitted_qc>March 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2010</study_first_posted>
  <last_update_submitted>March 29, 2010</last_update_submitted>
  <last_update_submitted_qc>March 29, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 30, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr AN Sulke</name_title>
    <organization>East Sussex NHS Trust</organization>
  </responsible_party>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Atrial Fibrillation Ablation</keyword>
  <keyword>Atrial Fibrillation monitoring</keyword>
  <keyword>Ablation Frontiers</keyword>
  <keyword>Reveal XT</keyword>
  <keyword>LASSO</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

